Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AJ5L
|
|||
| Former ID |
DAP001414
|
|||
| Drug Name |
Oxatomide
|
|||
| Synonyms |
Celtect; Oxatimide; Oxatomida; Oxatomidum; Oxetal; Tinset; CBMicro_024634; KW 4354; O 9387; R 35443; R35443; Celtect (TN); KW-4354; McN-JR 35443; Oxatomida [INN-Spanish]; Oxatomide (tinset); Oxatomidum [INN-Latin]; R 35,443; R-35443; Oxatomide (JAN/USAN/INN); Oxatomide [USAN:BAN:INN:JAN]; 1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-1,3-dihydro-2H-benzimidazol-2-one; 1-(3-(4-(Diphenylmethyl)-1-piperazinyl)propyl)-2-benzimidazolinone; 1-[3-(4-Benzhydryl-piperazin-1-yl)-propyl]-1,3-dihydro-benzoimidazol-2-one; 1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro-2H-benzimidazol-2-one; 1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-2-benzimidazolinone; 3-[3-(4-benzhydrylpiperazin-1-yl)propyl]-1H-benzimidazol-2-one
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hay fever [ICD-11: CA08.00; ICD-10: J30.1; ICD-9: 477] | Approved | [1] | |
| Therapeutic Class |
Antiallergic Agents
|
|||
| Company |
Janssen Pharmaceutica
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H30N4O
|
|||
| Canonical SMILES |
C1CN(CCN1CCCN2C3=CC=CC=C3NC2=O)C(C4=CC=CC=C4)C5=CC=CC=C5
|
|||
| InChI |
1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
|
|||
| InChIKey |
BAINIUMDFURPJM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 60607-34-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
454767, 855791, 3356790, 7434788, 7848836, 8076407, 8152832, 10589929, 11111579, 11171328, 12013337, 14782886, 17405482, 17447408, 24278615, 29223704, 47515476, 48259415, 49883312, 50100302, 50106789, 50106790, 53778030, 57322351, 78738974, 81093279, 85174443, 85231171, 89007468, 92304200, 92308943, 96099872, 103175665, 103928643, 104306919, 105054418, 124609729, 124799800, 124881005, 124881006, 125354189, 126685859, 127327792, 127327793, 127486604, 131320626, 134338621, 135260589, 137156392, 137260958
|
|||
| ChEBI ID |
CHEBI:31943
|
|||
| SuperDrug ATC ID |
R06AE06
|
|||
| SuperDrug CAS ID |
cas=060576138
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H1 receptor (H1R) | Target Info | Antagonist | [1], [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | Histamine H1 receptor mediated signaling pathway | |||
| Reactome | Histamine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| IL-4 Signaling Pathway | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. | |||
| REF 2 | Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. J Allergy Clin Immunol. 2003 Oct;112(4 Suppl):S78-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.